Communiqués Syncona Limited

Actions

BACT

GG00B8P59C08

Marché Fermé - London S.E. Autres places de cotation 17:35:29 15/07/2024			Varia. 5j.	Varia. 1 janv.
123 ^GBX	+1,65 %		+4,24 %	-0,32 %

08/07	Thor Energy commence à forer ; Deltic accepte la licence	AN
03/07	Syncona investit 42,5 millions de dollars supplémentaires dans Beacon Therapeutics	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Syncona : Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors	11/07	PU
Syncona : Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial	10/07	PU
Syncona : IOnctura announces expansion of roginolisib clinical trial program to NSCLC	09/07	PU
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies	04/07	AQ
Syncona : Notice of the 2024 Annual General Meeting	03/07	PU
Syncona : Spur Therapeutics Presents Promising New Data from its GBA1 Parkinson’s Disease Research Program	01/07	PU
IOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials	21/06	AQ
Syncona : Sustainability Report for the year ended 31 March 2024	20/06	PU
Syncona : Final Results for the period ending 31 March 2024	20/06	PU
Syncona : Full Year Results for the 12 months ended 31 March 2024	20/06	PU
Syncona : Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501	12/06	PU
Syncona : Quell Therapeutics Advances QEL 001, its Multi modular Engineered CAR Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients	05/06	PU
Syncona : Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study	29/05	PU
Syncona : Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production	09/04	PU
BEST OF THE BROKERS	08/04	AQ
Syncona : Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)	02/04	PU
Syncona : Autolus Therapeutics Announces Changes to its Board of Directors (1)	02/04	PU
Syncona : Anaveon announces publication of ANV419 Phase I data in The Journal for ImmunoTherapy of Cancer	14/12	PU
Syncona to Acquire Freeline Therapeutics	22/11	AQ
Syncona : SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer	16/10/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Syncona Limited

Actions

BACT

GG00B8P59C08

Communiqués

Filtres